Control of Mutagenic Impurities: Survey of Pharmaceutical Company Practices and a Proposed Framework for Industry Alignment
- 3 March 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 25 (4), 831-837
- https://doi.org/10.1021/acs.oprd.0c00517
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- New Semi-Automated Computer-Based System for Assessing the Purge of Mutagenic ImpuritiesOrganic Process Research & Development, 2019
- A consortium-driven framework to guide the implementation of ICH M7 Option 4 control strategiesRegulatory Toxicology and Pharmacology, 2017
- A Kinetics-Based Approach for the Assignment of Reactivity Purge FactorsOrganic Process Research & Development, 2015
- A Generic Industry Approach To Demonstrate Efficient Purification of Potential Mutagenic Impurities in the Synthesis of Drug SubstancesOrganic Process Research & Development, 2015
- Mutagenic Impurities: Precompetitive/Competitive Collaborative and Data Sharing InitiativesOrganic Process Research & Development, 2015
- Strategies To Address Mutagenic Impurities Derived from Degradation in Drug Substances and Drug ProductsOrganic Process Research & Development, 2015
- Mutagenic Alkyl-Sulfonate Impurities in Sulfonic Acid Salts: Reviewing the Evidence and Challenging Regulatory PerceptionsOrganic Process Research & Development, 2015
- Risk Assessment of Genotoxic Impurities in New Chemical Entities: Strategies To Demonstrate ControlOrganic Process Research & Development, 2013
- Mechanisms of Chemical Carcinogenicity and Mutagenicity: A Review with Implications for Predictive ToxicologyChemical Reviews, 2011
- A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicityRegulatory Toxicology and Pharmacology, 2006